Collegium Pharmaceutical, Inc. COLL Nucynta ER — Product revenues, net

Other product segments

Similar metrics at other companies

RYTMProduct revenue, net — Total revenues

$60.11M+59.4%

ESPRProduct sales, net — Total Revenues

$43.4M+24.3%

ARDXProduct sales, net — Total revenues

$93.37M+37.7%

EXELNet product revenues — Total revenues

$554.98M+8.1%

GERNProduct revenue, net — Total revenues

$51.77M+31.3%

BMRNNet product revenues — Total revenues

$760.08M+3.5%

Questions, answered.

What is Collegium Pharmaceutical, Inc.'s nucynta ER — product revenues, net?

Collegium Pharmaceutical, Inc. (COLL) reported nucynta ER — product revenues, net of $18.23M in Q1 2026.

How has Collegium Pharmaceutical, Inc.'s nucynta ER — product revenues, net changed year-over-year?

Collegium Pharmaceutical, Inc.'s nucynta ER — product revenues, net decreased by 7.4% year-over-year, from $19.69M to $18.23M.

What is the long-term trend for Collegium Pharmaceutical, Inc.'s nucynta ER — product revenues, net?

Over 4 years (2021 to 2025), Collegium Pharmaceutical, Inc.'s nucynta ER — product revenues, net has grown at a 3.4% compound annual growth rate (CAGR), from $70.94M to $80.99M.

What does nucynta ER — product revenues, net mean?

This metric represents the total net sales generated from the specific pharmaceutical product line after accounting for rebates, discounts, and returns. It serves as a key indicator of the product's market adoption, pricing power, and commercial performance within the company's specialty pain management portfolio. Monitoring this revenue stream helps investors assess the lifecycle stage and competitive positioning of the asset in the chronic pain treatment market.